

CURICULUM VITAE

Candidat: (*Nume, prenume*) ___ Ciuleanu Tudor-Eliade _____

A. Date personale

1. Nume: Ciuleanu
2. Prenume: Tudor Eliade
3. Data și locul nașterii: 14.02.1957
4. Cetățenie: Română
5. Stare civilă: căsătorit
6. Studii universitare absolvite (institutie, anul):

Universitatea de Medicină și Farmacie Iuliu Hatieganu Cluj-Napoca, Diploma # 377 / 1982

7. Limbi străine cunoscute și nivelul (atestat sau evaluare proprie):

Engleză – evaluare proprie – cursiv, scris, vorbit

Franceză – evaluare catedră UMF – cursiv, scris, vorbit

B. Informații despre activitatea profesională*

1. Calificare profesională actuală – medic primar, oncologie medicală (1993)
2. Competențe profesionale atestate - Doctorat în Oncologie, Universitatea de Medicină și Farmacie Iuliu Hatieganu Cluj-Napoca 1996, diploma #5200 / 1996

3. Alte specializări și calificări-

Specializare aprofundată în oncologie:

Universitatea de Medicina Paris Sud, Franța, 1991-1992

Certificare în Oncologie Medicală: European Society of Medical Oncology Certification Examination, Atena, 1998

4. Membru al asociațiilor profesionale

-Societatea Română de radioterapie și Oncologie Medicală (SRROM), Cluj-Napoca (1993 – prezent)

-Societatea Română Împotriva Cancerului, Cluj-Napoca (1993 – prezent)

-Societatea Națională de Oncologie Medicală din România (SNOMR), Craiova (2000 – prezent)

-The American Society of Clinical Oncology (ASCO) (1999 –prezent)

-Membru Certificat al European Society of Medical Oncology (ESMO) (1998 –prezent)

-The Central European Cooperative Oncology Group, Viena, Austria (CECOG) (1998 – prezent)

-The Balkan Union of Oncology, Atena, Grecia (BUON) (1996 – prezent)

-The French Cancer Society, Paris, Franța (1992 – 1998)

-National Cancer Institute of Canada Study Group (NCIC, Toronto) (2003 –prezent)

-International Association for the study of Lung Cancer (IASCLC) (2006 –prezent)

5. Contributii profesionale notabile

- *participare activă la cercetarea științifică sub forma trialurilor clinice, majoritatea multicentrice, internaționale, din 1991 (80 trialuri până în prezent)*

- în ansamblu, prin recrutarea activă din studiile la care am participat, Institutul Oncologic Ion Chiricuță a ocupat unul dintre primele locuri între instituțiile care au dus la înregistrarea unor molecule noi (erlotinib, pemetrexed, topotecan oral, generice de G-CSF, etc.) sau au confirmat valoarea unor strategii de tratament (chimioterapia adjuvantă, chimioterapia de întreținere, chimioterapia de ratrapaj în cancerele pulmonare non-microcelulare sau chimioterapia de salvare în cancerele pulmonare cu cellule mici).

-aceste studii s-au concretizat în publicații ISI (vezi lista anexată) și au constituit subiectul unor prezentări orale în cadrul ASCO, ESMO, IASLC, etc.

C. Informatii despre activitatea didactică**

1. Grad didactic si anul dobândirii

Conferentiar Universitar, UMF Cluj-Napoca (2004)

Sef de lucrări, UMF Cluj-Napoca (1997)

Asistent Universitar, UMF Cluj-Napoca (1993)

2. Activitate didactică universitară (cursuri, stagii)

a. Licență – conducător a 32 teze diplomă

b. Master - nu

c. Conducere de doctorat - nu

3. Activitate didactică postuniversitară (cursuri si / sau stagii desfășurate)

-Organizare cursuri postuniversitare: 8

Curs “Post ASCO” (2005),

Curs “Actualități in Terapia Moleculară tintită” (2006-2012)

-Invited speaker la cursuri postuniversitare internationale: 7

-Curs ASCO – Chicago, USA - 1.06.2012- Lung Cancer Management in Romania

-Curs ASCO – Poiana Brasov oct. 2012 – Clinical trials in Romania

-Curs ESMO – Sinaia, 2012 – Debate on Maintenance Therapy in Lung cancer – the Pros

-Curs ASCO – Poiana Brasov oct. 2011 – Maintenance Therapy for Advanced NSCLC

-Curs ASCO – Cluj-Napoca, iunie 2011– Workshop in Clinical Trials

-Curs BSO (Balkan School of Oncology), Volos, Grecia - 2005 – Targeted Treatments in Cancer

4. Materiale didactice produse

Cărți / cursuri publicate: 2 (vezi tabelul mai jos)

Capitole publicate în volume colective: 20 (vezi tabelul mai jos)

In România: 18

In străinătate: 2 (Grecia, SUA)

Compact discuri, alte materiale didactice:

Compact disc conținând datele cursului postuniversitar Post ASCO/ Terapie Moleculară tintită (2011 și 2012)

5. Realizări deosebite în domeniul didactic ***

-Redactarea unor capitole din cursurile de Oncologie generală pentru studenți ale catedrei de oncologie-radioterapie (în limbile română, engleză și franceză) și a caietelor de lucrări practice (Propedeutica Oncologică).

-Organizarea anuală, începând cu 2005, a unor cursuri postuniversitare de "Actualități în terapia moleculară tintită"

D. Informații despre activitatea științifică ****

Doctor în științe din anul 1996

Doctorat în Oncologie, Universitatea de Medicină și Farmacie Iuliu Hatieganu Cluj-Napoca, diploma #5200 / 1996

1. Lucrări ISI

1. Bjørn H Grønberg; Tudor Ciuleanu; Øystein Fløtten; Aija Knuuttila; Edvard Abel; Seppo W Langer; Kurt Krejcy; Astra M Liepa; Maria Munoz; Marjo Hahka-Kemppinen; et al.

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

Lung Cancer 78, 63 (2012)

The Cancer Clinic, St. Olavs Hospital-Trondheim University Hospital, Norway.
bjorn.h.gronberg@gmail.com

2. V Golfinopoulos; G Pentheroudakis; A Goussia; V Siozopoulou; M Bobos; D Krikelis; A Cervantes; T Ciuleanu; M Marselos; G Fountzilas; et al.

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.

Ann. Oncol. 23, 2725 (2012)

Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.

3. George R Blumenschein; Tudor Ciuleanu; Francisco Robert; Harry J M Groen; Tiziana Usari; Ana Ruiz-Garcia; Lesley Tye; Richard C Chao; Erzsebet Juhasz

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.

J Thorac Oncol 7, 1406 (2012)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-1402, USA.
gblumens@mdanderson.org

4. Dimitrios Krikelis; George Pentheroudakis; Anna Goussia; Vassiliki Siozopoulou; Matheos Bobos; Dimitrios Petrakis; Aikaterini Stoyianni; Vassilios Golfopoulos; Andres Cervantes; Tudor Ciuleanu; et al.

Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Clin. Exp. Metastasis 29, 603 (2012)

Department of Medical Oncology, Medical School, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece.

5. E F Smit; M A Socinski; B P Mullaney; S P Myrand; G V Scagliotti; P Lorigan; M Reck; T Ciuleanu; J von Pawel; N A Karaseva; et al.

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.

Ann. Oncol. 23, 1723 (2012)

Department of Pulmonary Diseases, Vrije University Medical Center, Amsterdam, The Netherlands. ef.smit@vumc.nl

6. T Brodowicz; T Ciuleanu; J Crawford; M Filipits; J R Fischer; V Georgoulas; C Gridelli; F R Hirsch; J Jassem; P Kosmidis; et al.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

Ann. Oncol. 23, 1223 (2012)

Clinical Division of Oncology, Comprehensive Cancer Center, Medical University Vienna-General Hospital, Vienna, Austria.

7. Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenias; Skaidrius Miliuskas; Alexandru Calin Grigorescu; Carina Hillenbach; Hrefna Kristin Johannsdottir; Barbara Klughammer; Emilio Esteban Gonzalez

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Lancet Oncol. 13, 300 (2012)

Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania. tudor@iocn.ro

8. Eduard Vrdoljak; Tudor Ciuleanu; Galina Kharkevich; Jozef Mardiak; Michal Mego; Peeter Padrik; Luboš Petruželka; Gunta Purkalne; Yaroslav Shparyk; Breda Skrbinc; et al.

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.

Expert Opin Pharmacother 13, 159 (2012)

Department of Oncology, University Hospital Split, Split, Spinciceva 1, 21000 Split, Croatia. eduard.vrdoljak@st.htnet.hr

9. G Fountzilas; E Ciuleanu; M Bobos; A Kalogera-Fountzila; A G Eleftheraki; G Karayannopoulou; T Zamboukas; A Nikolaou; K Markou; L Resiga; et al.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

Ann. Oncol. 23, 427 (2012)

Department of Medical Oncology Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. fountzil@auth.gr

10. C Le Péchoux; A Laplanche; C Faivre-Finn; T Ciuleanu; R Wanders; D Lerouge; R Keus; M Hatton; G M Videtic; S Senan; et al.

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

Ann. Oncol. 22, 1154 (2011)

Radiation Oncology Department, Institut Gustave-Roussy, Villejuif, France. lepechoux@igr.fr

11. Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; et al.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Int. J. Cancer 127, 2209 (2010)

Department of Surgery, Cologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, Germany.

12. Federico Cappuzzo; Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenias; Aleksandra Szczésna; Erzsébet Juhász; Emilio Esteban; Olivier Molinier; Wolfram Brugger; Ivan Melezínek; et al.

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Lancet Oncol. 11, 521 (2010)

Department of Medical Oncology, Ospedale Civile di Livorno, Livorno, Italy.
f.cappuzzo@usl6.toscana.it

13. Tudor Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krzakowski; Eckart Laack; Yi-Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; et al.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Lancet 374, 1432 (2009)

Oncological Institute Ion Chiricuta, Cluj, Romania.

14. Mark A Socinski; Egbert F Smit; Paul Lorigan; Kartik Konduri; Martin Reck; Aleksandra Szczesna; Johnetta Blakely; Piotr Serwatowski; Nina A Karaseva; Tudor Ciuleanu; et al.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer.

J. Clin. Oncol. 27, 4787 (2009)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. socinski@med.unc.edu

15. Pol M Specenier; Tudor Ciuleanu; Jane E Latz; Luna C Musib; Christelle L S Darstein; Jan B Vermorken

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.

Cancer Chemother. Pharmacol. 64, 233 (2009)

Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium.

16. Ulrich Gatzemeier; Tudor Ciuleanu; Mircea Dediu; Elena Ganea-Motan; Heinz Lubenau; Auro Del Giglio

XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.

J Thorac Oncol 4, 736 (2009)

Center of Pneumology and Thoracic Surgery, Department of Thoracic Surgery, Grosshansdorf, Germany. pneumo.onko@t-online.de

17. Tudor E Ciuleanu; Alexander V Pavlovsky; Gyorgy Bodoky; Avgust M Garin; Virginia K Langmuir; Stewart Kroll; George T Tidmarsh

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

Eur. J. Cancer 45, 1589 (2009)

Ion Chiricuta Cancer Institute, 34-36 Gh. Bilascu St., Cluj-Napoca, Cluj 400015, Romania. tudor@iocn.ro

18. Cécile Le Péchoux; Ariane Dunant; Suresh Senan; Aaron Wolfson; Elisabeth Quoix; Corinne Faivre-Finn; Tudor Ciuleanu; Rodrigo Arriagada; Richard Jones; Rinus Wanders; et al.

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

Lancet Oncol. 10, 467 (2009)

Radiotherapy Department, Institut Gustave-Roussy, Villejuif, France. lepechoux@igr.fr

19. Corey J Langer; Kenneth J O'Byrne; Mark A Socinski; Sergei M Mikhailov; Krzysztof Leśniewski-Kmak; Martin Smakal; Tudor E Ciuleanu; Sergey V Orlov; Mircea Dediu; David Heigener; et al.

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

J Thorac Oncol 3, 623 (2008)

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. cj_langer@fccc.edu

20. Robert E Smith; Matti S Aapro; Heinz Ludwig; Tamás Pintér; Martin Smakal; Tudor E Ciuleanu; Li Chen; Tom Lillie; John A Glaspy

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

J. Clin. Oncol. 26, 1040 (2008)
South Carolina Oncology Associates, Columbia, SC, USA.

21. E Ciuleanu; A Irimie; T E Ciuleanu; V Popita; N Todor; N Ghilezan

Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.

J BUON 13, 37 (2008)
Cancer Institute Ion Chiricuta, Cluj, Romania.

22. Dan Radulescu; Sorin Pripon; Tudor E Ciuleanu; Letitia I Radulescu

Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor.

Clin Lung Cancer 8, 504 (2007)
Department of Internal Medicine, 5th Medical Clinic, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.

23. Alexandru Grigorescu; Tudor Ciuleanu; Elena Firoiu; Delia Ruta Muresan; Gabriela Teodorescu; Bruce R Basson

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).

Lung Cancer 57, 168 (2007)
Department of Medical Oncology, Bucharest Oncology Institute, Bucharest, Romania.
agrigorescu@iob.ro

24. T Ciuleanu; M Diculescu; N M Hoepffner; J Trojan; V Sailer; M Zalupski; T Herrmann; A Roth; J Chick; K Brock; et al.

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.

Invest New Drugs 25, 385 (2007)
Oncology Institute Ion Chiricuta, 34-36 Gh. Bilascu Street, 3400, Cluj-Napoca, Romania.
tudor@iocn.ro

25. D Radulescu; S Pripon; D Bunea; T E Ciuleanu; L I Radulescu

Endocrine paraneoplastic syndromes in small cell lung carcinoma. Two case reports.

J BUON 12, 411 (2007)

5th Medical Clinic, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. dan_rad31@yahoo.com

26. D Radulescu; S Pripon; A Parv; C Duncea; T E Ciuleanu; L I Radulescu

Myocardial function in patients with breast cancer after therapy with anthracyclines and chest irradiation.

J BUON 12, 349 (2007)

Department of Cardiology, 5th Medical Hospital, University of Medicine Cluj, Cluj, Romania. dan_rad31@yahoo.com

27. Dan Radulescu; Sorin Pripon; Andreea Parv; Caius Duncea; Tudor E Ciuleanu

Altered left ventricular diastolic performance in oncologic patients treated with epirubicin.

Congest Heart Fail 13, 215 (2007)

Department of Internal Medicine, Fifth Medical Clinic, Cluj-Napoca, Romania. dan_rad31@yahoo.com

28. P Rusu; T E Ciuleanu; D Cernea; D Pelau; V Gaal; C Cebotaru; T Guttman; N Todor; N Ghilezan

Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.

J BUON 12, 33 (2007)

Department of Radiotherapy, Institute of Oncology Prof. Ion Chiricuta, Cluj - Napoca, Romania. petronelarusu@yahoo.com

29. Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

J. Clin. Oncol. 24, 5441 (2006)

Royal Marsden Hospital, National Health System Trust, Sutton, Surrey, England. mary.o'brien@rmh.nhs.uk

30. Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; et al.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

J. Clin. Oncol. 24, 5034 (2006)

University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA. Fred.Hirsch@UCHSC.edu

31. Thomas Brodowicz; Maciej Krzakowski; Matjaz Zwitter; Valentina Tzekova; Rodryg Ramlau; Nicolae Ghilezan; Tudor Ciuleanu; Branka Cucevic; Kalman Gyurkovits; Ernst Ulsperger; et al.

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Lung Cancer 52, 155 (2006)

Medical University Hospital, Vienna, Austria.

32. Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; et al.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Lancet 366, 1527 (2005)

Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. nick.thatcher@christie-tr.nwest.nhs.uk

33. Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; et al.

Erlotinib in previously treated non-small-cell lung cancer.

N. Engl. J. Med. 353, 123 (2005)

Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada.

34. D Radulescu; C Duncea; T E Ciuleanu; L I Radulescu; T Gal; I Cimpean

Does epirubicin affect left ventricular systolic performance in oncologic patients?

J BUON 10, 77 (2005)

5th Medical Hospital, Medical University Cluj, Cluj, Romania.

35. T E Ciuleanu; G Fountzilas; E Ciuleanu; M Plataniotis; N Todor; N Ghilezan

Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study.

J BUON 9, 161 (2004)

Cancer Institute Ion Chiricuta, Cluj, Romania.

36. George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; et al.

Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Med. Oncol. 21, 95 (2004)

AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

fountzil@med.auth.gr

37. T E Ciuleanu; R Curcă; D Iancu; N Todor; C Cebotaru; I Radulescu; E Banu; N Ghilezan

First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study.

J BUON 7, 43 (2002)

University of Medicine and Pharmacy "I. Hatieganu" Cluj-Napoca, Romania.

38. *Ciuleanu E, Ghilezan N, Todor N, Ciuleanu TE*

Ho's versus UICC classification for nasopharyngeal carcinoma.

Journal of BUON., vol. 2, no. 2, 1997, 75-180

39. *Cebotaru C, Ghilezan N, Todor N, Ciuleanu TE*

Combination therapy and secondary resection results in patients with testicular germ cell tumors. The Oncological Institute of Cluj Napoca experience.

Journal of BUON., vol. 2, no. 2, 1997, 161-170

2. Lucrări BDI

1	Neoadjuvant BEC 'Highly Active' Against UCNT - <i>Ciuleanu TE, Ghilezan N, Ciuleanu E, Cernea V, Todor N, Udrea A, L Vâță</i>	Oncology News, vol. 21, no.6, 1995, p 1 & 6	1995
---	--	--	------

3. Cărti

Cărti / cursuri publicate: 2

Nr.	TITLE	nr. pag.	publisher	City	Year
1	Carcinoamele Bronhopulmonare - Principii și practică <i>TE Ciuleanu</i>	421	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 973-693-001-7	Cluj-Napoca	2003
2	Extinderea limitelor in managementul bolnavului oncologic – terapia moleculară tinită a tumorilor solide Curs postuniversitar VM Nagy, TE Ciuleanu	268	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-325-7	Cluj-Napoca	2009

4. Capitole

Capitole publicate în volume colective: 20

In România: 18

In străinătate: 2 (Grecia, SUA)

1	Carcinoamele colorectale p.421-436	-Lazăr L, Bădulescu FI, Cebotaru C, Ciuleanu T, Rancea A/ Editor, Leonida Gherasim, Colegiul Medicilor Romania/ Ghiduri de practică medicală - vol I	Info Medica ISBN 973-9394-32-9	Bucuresti	1999	16
2	Metode de tratament-chimioterapie, p.72-79	Viorica M Nagy, Nicolae Ghilezan/ Curs de Oncologie	Editura Mediamira ISBN 973-9358-26-8	Cluj-Napoca	1999	9
3	Metode de tratament-hormonoterapie, p.80-84	Viorica M Nagy, Nicolae Ghilezan/ Curs de Oncologie	Editura Mediamira ISBN 973-9358-26-8	Cluj-Napoca	1999	5
4	Carcinoamele bronhopulmonare p 93-102	Viorica M Nagy, Nicolae Ghilezan/ Curs de Oncologie	Editura Mediamira ISBN 973-9358-26-8	Cluj-Napoca	1999	10
5	Cancerle digestive p 123-135	Viorica M Nagy, Nicolae Ghilezan/ Curs de Oncologie	Editura Mediamira ISBN 973-9358-26-8	Cluj-Napoca	1999	13
6	Limfoamele maligne p165-174	Viorica M Nagy, Nicolae Ghilezan/ Curs de Oncologie	Editura Mediamira	Cluj-Napoca	1999	10

		Curs de Oncologie	ISBN 973-9358-26-8			
7	Carcinoamele bronhopulmonare p.77-100	Ciuleanu TE/ Editor, Leonida Gherasim, Colegiul Medicilor din Romania - Ghiduri de practică medicală - vol II	Info Medica ISBN 973-9394-69-8	Bucuresti	2001	23
8	Cancerul bronhopulmonar p.58-72	Viorica M Nagy/ Propedeutică Oncologică	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 973-8385-96-2	Cluj-Napoca	2003	15
9	Cancerlele digestive p.125-166	Viorica M Nagy/ Propedeutică Oncologică	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 973-8385-96-2	Cluj-Napoca	2003	42
10	Targeted therapy of lung cancer: the present and the future p.141-154	AE Athanassiou/ Balkan School of Oncology	J BUON ISSN 1107-0625	Piraeus, Greece	2005	14
11	Principiile chimioterapiei si hormonoterapiei P 118-139	Viorica Nagy/ Principii de cancerologie generala	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-232-8	Cluj-Napoca	2007	22
12	Terapia moleculara tintita si alte tratamente biologice P 139-155	Viorica Nagy/ Principii de cancerologie generala	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-232-8	Cluj-Napoca	2007	17
13	Cancerul bronhopulmonar P 64-78	Viorica Nagy/ Propedeutică Oncologică Editia a II-a revizuită si adăugită	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-291-5	Cluj-Napoca	2008	15
14	Cancerlele digestive P 135-176	Viorica Nagy/ Propedeutică Oncologică Editia a II-a revizuită si adăugită	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-	Cluj-Napoca	2008	42

			973-693-291-5			
15	The principles of Chemotherapy and Hormonal Treatment P 93-112	Ed. Kacso Gabriel/ Cancer. Principles and Practice of General Oncology	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-342-4	Cluj-Napoca	2009	20
16	Molecular Targeted Therapy and Other Biological Treatments P 113-126	Ed. Kacso Gabriel/ Cancer. Principles and Practice of General Oncology	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-342-4	Cluj-Napoca	2009	14
17	Les Principes Generales de la Chimiotherapie P 66-87	Viorica Magdalena Nagy / Cancerologie. Principes generaux biologiques et cliniques	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-335-6	Cluj-Napoca	2009	20
18	Therapie moleculaire ciblee et autres traitements biologiques P 88-105	Viorica Magdalena Nagy / Cancerologie. Principes generaux biologiques et cliniques	Editura Medicală Universitară "Iuliu Hațieganu" ISBN 978-973-693-335-6	Cluj-Napoca	2009	20
19	Maintenance chemotherapy for advanced NSCLCŞ a valuable concept P 228-254	Alexandru C. Grigorescu, Lodovico Balducci, Florinel Bădulescu/ Update in Medical Oncology	Editura Medicală ISBN 978-973-39-0724-4	Bucureşti	2011	27
20	Tudor E. Ciuleanu: Research and Standard of Care: Lung Cancer in Romania. P 437-442	In: Ramaswamy Govindan (sub red.). American Society of Clinical Oncology Educational Book 2012,	Ed. American Society of Clinical Oncology, Alexandria, VA 2012: 437-442 (ISSN 1548-8748)	Alexandria VA, USA	2012	6

5. Granturi

a. Director / conducere:

-Director: PN-II-2011 30753 – Detectia precoce a recaderilor postterapeutice in adenocarcinoamele coloretale prin urmarirea unor parametrii tumorali si imunologici sangvini. (2011 – prezent)

-Mentor: PN-II-RU-PD-2012-3-0111-Detectia si Tratamentul Celulelor Tumorale Circulante Metastatice Chimiorezistente utilizand Nanoparticule de Metal Nobil Bioconjugate. (2012 –prezent)

b. Membru :

- CEEEX: Sisteme inteligente de detectare si evaluare neinvaziva a fibrozei, restructurarii si a nodulilor displazici ai ficatului cu ajutorul ultrasonografiei 2D/3D si a markerilor molecular, SIFE. (2006 – 2008)

-CEEEX: Predictia evolutiei si estimarea raspunsului la tratament a tumorilor maligne, prin modelare morfologica si hemodinamica, utilizand tehnici imagistice, matematice si de inteligenta artificiala, ANGIOTUMOR. (2006 – 2008)

-CEEEX-III: Radiobiologia: mecanisme moleculare si aplicatii in tratamentul cancerului, RADMOBIO. (2006 – 2007)

6. Valoarea granturilor câștigate ca director / conducător : 1.391.400 Ron ;
300.000 Ron

7. Brevete de inventie / inovatie
Documentatia depusă (mai 2012) pentru obtinerea unui brevet de inventie pentru un Program informatic de prescriere automatizată a chimioterapiei (autori N. Todor, TE Ciuleanu)

8. Membru în societăți științifice

-Societatea Română de radioterapie si Oncologie Medicală (SRROM), Cluj-Napoca (1993 – prezent) (Presedinte al SRROM 2002-2003)

-Societatea Română Împotriva Cancerului, Cluj-Napoca (1993 – present)

-Societatea Natională de Oncologie Medicală din România (SNOMR), Craiova (2000 – prezent)

-The American Society of Clinical Oncology (ASCO) (1999 –prezent)

-Membru Certificat al European Society of Medical Oncology (ESMO) (1998 –prezent)

-The Central European Cooperative Oncology Group, Viena, Austria (CECOG) (1998 – prezent)

-The Balkan Union of Oncology, Atena, Grecia (BUON) (1996 – prezent) (Reprezentant Național al României în BUON - 2000 - prezent)

-The French Cancer Society, Paris, France (1992 – 1998)

-National cancer Institute of Canada Study Group (NCIC, Toronto) (2003 –prezent)

-International Association for the study of Lung Cancer (IASCLC) (2006 –prezent)

9. Participări la manifestări științifice internaționale:

7-10.11.92	Lyon, Franta	ESMO	17 th ESMO Congress	
11.93	Ierusalim, Israel	Federation of the European Cancer	ECCO 7	

		Societies		
12-18.11.94	Lisabona, Portugalia	ESMO	17 th ESMO Congress	
28-31.05.95	Praga, Cehia	IASLC	3 rd Central European Conference on Lung Cancer	
29.10-2.11.95	Paris, Franța	Federation of the European Cancer Societies	ECCO 8	Rouesse J, van Oosterom AT
17-20.07.97	Salonic, Grecia	Aristoteles Interuniversity	Recent advances in diagnostic imaging and supportive care in oncology	Molls M, Vritsios
12-15.05.97	Denver, SUA	ASCO	33th annual Meeting	
10-15.08.97	Dublin, Irlanda	IASLC	8th World Conference on Lung Cancer	Carney D
14-18.09.97	Hamburg, Germania	Federation of the European Cancer Societies	ECCO 9	Horiot JC, Herfahrt CH
10.97	Montreux, Elvetia	Smithkline Beecham	Hycamtin worldwide meeting	
15-19.05.98	Los Angeles, SUA	ASCO	34th Annual Meeting and Satellite Symposia	Dinkel MK
16-19.05.98	Los Angeles, SUA	ASCO	34th annual Meeting of ASCO	Dinkel MK
26-30.08.98	Naoussa and Mount Athos, Grecia	Aristoteles Interuniversity	Colo-rectal cancers. From clinical research to standard practice	Gerard JP, Vritsios A
10-14.09.98	Kuşadasi, Turcia	BUON	2nd BUON Congress	Kinay M, Antypas G
10.98	Nassau, Bahamas	Smithkline Beecham	Hycamtin worldwide meeting	
6-10.11.98	Atena, Grecia	ESMO	23rd ESMO Congress 25 credite ESMO-MORA	Hossfeld DK, Kosmidis PA
05.99	Atlanta, SUA	ASCO	35th annual Meeting of ASCO	
24-25.06.99	Indianapolis, SUA	Lilly	First International Lilly Oncology Young Investigators' Meeting	Pedderson A, Einhorn L
12-16.09.99	Viena, Austria	Federation of the European Cancer Societies	ECCO 10	O'Higgins, Kogelink HD, Tursz T
26-27.09.99	Oxford, Anglia	Medical Research Council	The UKCCCR National Colorectal Cancer Trials Meeting 8 credite I	Barnwell J
17-23.05.00	Indianapolis, SUA	Lilly	Global Medical Conference/ ASCO	Pedersen A
20-23.05.00	New Orleans, SUA	ASCO	36th annual Meeting of ASCO	Whippen D
24-25.09.00	Oxford, Anglia	UKCCCR	UKCCCR National Colorectal Cancer Trials Meeting	Barnwell J
13-17.10.00	Hamburg,	ESMO	25th ESMO Congress	Tonato M

	Germania			Hossfeld DK
8.-11.11.00	New York, SUA	The Page and William Black Post-Graduate School/ The Mount Sinai School of Medicine	Chemotherapy Foundation - Innovative Cancer Therapy for Tomorrow	Swartz M, Dean MD
8-9.03.01	Londra, Anglia	European School of Oncology	Colorectal Cancer Conference	U. Veronesi
30.04-3.05.01	Barcelona, Spania	IASLC, Spanish Lung Cancer Study Group	7th IASLC Lung Cancer Biology Workshop	Rossell R
10-15.05.01	San Francisco, SUA	ASCO	2001 Annual Meeting and Educational Symposia	McIntyre M
29.08-1.09.01	Salonic, Grecia	Aristoteles Interuniversity	Multidisciplinary approach in oncology & treatment planning	Guduric B, Vritsios A
23-24.09.01	Oxford, Anglia	UKCCR	The UKCCCR National Colorectal Cancer Trials Meeting	Barnwell J
21-25.10.01	Lisabona, Portugalia	FECS	ECCO 11	dos Santos G, Hossfeld DK, Glaus A, zur Hausen H
20-21.04.02	Viena, Austria	CECOG	2 nd International Forum on Oncology and Health Economics	Zielinski CC
30.06-5.07.02	Oslo, Norvegia	UICC	18th UICC International Cancer Congress	Kvinnsland S
28-29.09.02	Chicago, SUA	ASCO	ASCO/NCI Scientific Symposium: Molecular Oncology for the Clinical Oncologist.	McIntyre M
18.10.02	Nisa, Franta	ESMO	27 th ESMO Congress	Ludwig E
15-16.11.02	Barcelona, Spania	Spanish Lung Cancer Study Group	Perspectives in Lung Cancer	
23-24.11.02	Atena, Grecia	BUON	4th Congress of the Balkan Union Of Oncology	Vassilopoulos PP, Athanassiou AE
1-4.02.03	Paris, Franta	ICACT	14 th International Congress on Anti-Cancer Treatment	
31.05-3.06.03	Chicago, SUA	ASCO	2003 Annual Meeting	Cummings Ch.
10-14.08.03	Vancouver, Canada	University of British Columbia	10th World Conference on Lung Cancer	Kendali Ho, Bluman R
21-25.09.03	Copenhaga, Danemarca	FECS	ECCO 12	Gullick WJ, Overgaard J, Vaessen G
25-26.10.2003	Paris, Franta	Roche	Building Bridges with Xeloda	Namer M, Cassidy J

28-29.11.03	Monte Carlo, Monaco	Imedex	4th European Conference Perspectives in Lung Cancer	
4-8.06.2004	New Orleans, SUA	ASCO	2004 Annual Meeting	
17-19.06.2004	Rodos, Grecia	ESMO	ESMO Advance course - New Perspectives: Chest Tumors Integration of Research and Treatment	Bafakoulos DJ, Kosmidis P
21-25.09.2004	Barcelona, Spania	World Institute of Pain	3rd World Congress of the World Institute of Pain	Ruiz-Lopez R
14-17.10.2004	Belgrad, Serbia & Muntenegru	BUON	5th Congress of BUON	Athanassiou A
29.10-2.11.2004	Viena, Austria	ESMO	29th ESMO Congress 28 CME	Kosmidis P
18.11.2004	Praga, Cehia	Fresenius Biotech	Investigator Meeting	Wiest A, Lahr A
19-20.11.2004	Berlin, Germania	Imedex	5th European Conference Perspectives in Lung Cancer	Postmus PE, Scagliotti GV
22-23.11.2004	Milano, Italia	Novartis, Institutul Național de Cancer Milano	Clinical Stages on Gastrointestinal Stromal Tumors (GIST)	Casali PG
21-23.01.2005	Bologna, Italia	European Society of Oncological Urology (ESOU)	2nd Meeting of ESOU. Controversies in the management of bladder cancer and prostate cancer	
27-29.01.2005	Hollywood, Florida, SUA	ASCO	2005 Gastrointestinal Cancers Symposium	Cummings CC
2-3.12. 2006	Guangzhou, China,	Roche	Tarceva Integrated Meeting of Excellence	
13-14.02. 2007	Bangkok, Thailanda,	Roche	Tarceva Integrated Meeting of Excellence	
20-22.10.2005	Chișinău, Moldova	Inst Oncol Chișinău	National Congress of Oncology	
10-11.12.2005	Amsterdam, Olanda	Roche	Tarceva Scientific Symposium, 10-11 Dec. 2005	
7-8.04.2006	Cracoia, Polonia	IMMT	6 th International Medical Education Workshop Molecular Targeted Therapy of Cancer	JP Armand
24-26.03. 2006	Kuala Lumpur, Malaezia	Roche	- Roche Middle East Conference on Lung Cancer, Kuala Lumpur,	

18-19 April, 2006	Viena, Austria	Lilly	Alimta Investigator Meeting	
16.06.2007	Barcelona, Spania	Roche	Tarceva awareness day – Barcelona	
04.2007	Jeju Island, Corea	Roche	Integrating Tarceva in the treatment of NSCLC	
05.2007	Moscova, Rusia	Roche	Tarceva Integrated Meeting of Excellence	
07.2007	Viena, Austria	CECOG	Colorectal cancer Consensus Conference	Zielinski C
05.2008	Chicago, SUA	ASCO	44 th annual meeting	
09.2008	Stockholm, Suedia	ESMO	33 rd Esmo congress	
05.2009	Orlando, SUA	ASCO	45 th annual meeting	
08.2009	San Francisco, SUA	WCLC	13 th world lung cancer congress	
09.2009	Berlin, Germania	ECCO/ESMO	ECCO 15 and 34 th ESMO congress	
02.2010	Paris, Franta	ICACT	21 st International Congress on Anti-Cancer Treatment	
06.2010	Chicago, SUA	ASCO	46 th annual meeting	
10.2010	Milano, Italia	ESMO	35 th ESMO Congress	
02.2011	Paris, Franta	ICACT	22 nd International Congress on Anti-Cancer Treatment	
06.2011	Chicago, SUA	ASCO	47 th Annual meeting	
09.2011	Stockholm, Suedia	ESMO	36 th Esmo Congress	
02.2012	Paris, Franta	ICACT	23 rd International Congress on Anti-Cancer Treatment	
06.2012	Chicago, SUA	ASCO	48 th Annual Meeting	
09.2012	Viena, Austria	ESMO	37 th Esmo Congress	
10.2012	Sydney, Australia	ECLC, IASLC	15 th World Congress Lung Cancer	
06.2013	Chicago, SUA	ASCO	49 th Annual Meeting	
09.2013	Amsterdam, Olanda	ECCO/ ESMO	38 th ESMO Congress	

În lista participării la manifestări științifice naționale, menționez participarea anuală la Congresele SRROM, SNOMR, din momentul înființării acestora, ca și la toate Zilele Institutului Oncologic Cluj, București și Iași.

E. Informatii despre vizibilitate / prestigiu

1. Premii acordate drept recunoaștere a rezultatelor activității profesionale / științifice
Lucrarile ISI premiate de catre UEFISCDI in 2010 si 2012

2. Distinctii / decoratii - Nu
 3. Titluri onorifice ale altor institutii - Nu
 4. Membru în comitete de conducere ale unor organizatii stiintifice / profesionale
 - a. Nationale : Presedinte al SRROM 2002-2003
 - b. Internationale : Reprezentant National în BUON (2000-prezent)
 5. Membru în structuri nationale / internationale cu atributii de decizie profesională / stiintifică (CNATDCU, CNCS, comisii MS etc.)
- Membru al Consiliului stiintific al Agentiei Nationale a Medicamentului (ANM) (1998-2003)
- Expert al ANM în relatie cu European Medicines Agency (EMA) (2007-prezent)
- Membru al Comisiei de Experti în Oncologie a Casei Nationale de Asigurări de Sănătate (2006-prezent)
- Membru al Comisiei de Oncologie a Ministerului Sănătății Publice (Președinte al Comisiei de Oncologie Medicală) (2007-prezent)
6. Membru al academiilor profesionale - Nu
 7. Membru al Academiei Române - Nu

F. Alte informatii care se pot dovedi relevante privind experienta si capacitatea managerială

- functii în administratie în universitate / spital etc. –
- Coordonator al secției de oncologie medicală (1998) și a Spitalului de zi (1997-2003)

Data

7.10.2013

Semnătura,

Tudor Eliade Ciuleanu